Ugur Sahin Sells 15,000 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00. Following the transaction, the chief executive officer directly owned 553,209 shares in the company, valued at $53,157,852.81. This trade represents a 2.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Trading Down 0.9%

Shares of BioNTech stock traded down $0.86 on Wednesday, hitting $95.83. The stock had a trading volume of 407,411 shares, compared to its average volume of 1,104,336. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The stock’s 50-day simple moving average is $97.13 and its two-hundred day simple moving average is $95.10. The stock has a market cap of $24.23 billion, a price-to-earnings ratio of -12.24 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.60) earnings per share. As a group, sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on BNTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Finally, Berenberg Bank set a $140.00 price objective on BioNTech in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently bought and sold shares of the stock. Flossbach Von Storch SE purchased a new position in shares of BioNTech during the 2nd quarter worth approximately $207,142,000. BNP Paribas Financial Markets boosted its position in shares of BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares in the last quarter. Bank of America Corp DE grew its stake in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares during the period. First Trust Advisors LP grew its stake in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after purchasing an additional 451,124 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in BioNTech in the second quarter worth $39,385,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.